Details of the Drug Reposition

General Information of This Drug (ID: DMN45IC)

Drug Name
AFM13   DMN45IC
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Peripheral T-cell lymphoma DISCDT4E 2A90.C Phase 2 [1]
Mycosis fungoides DIS62RB8 2B01 Phase 2 [1]
Hodgkin lymphoma DISX2OUL 2B30 Phase 2 [2]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Lymphoma DISN6V4S 2A80-2A86 Phase 1/2 [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04101331) Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02321592) GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)